JNJ
JOHNSON & JOHNSON
NYSE: JNJ · New Brunswick, NJ · Healthcare
$237.00+4.84 (+2.08%)Closed
Market Cap$570.51B
Cash$22.05Bmost recent
Runwayprofitable
P/E (TTM)21.5EPS $11.03
52-Wk Range$146.14 – $247.14
Avg Volume8.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$237.00+70.5%
Pipeline

Drug candidates sponsored by JOHNSON & JOHNSON · ClinicalTrials.gov

87 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Placebo
Infant, Premature+2 more
Completed
2007-02past
2
Phase 4Oral Risperidone
Schizophrenia
Completed
2008-07past
1
Phase 4Abilify
Schizophrenia+1 more
Completed
2009-01past
1
Phase 4Unnamed
Healthy
Completed
2021-02-01past
1
Phase 4Unnamed
Gingivitis+1 more
Completed
2022-04-14past
1
Phase 4Guselkumab
Arthritis, Psoriatic
Recruiting
2027-06-05
1
Phase 4Fentanyl transdermal therapeutic system
Pain
Completed—1
Phase 4Quetiapine
PTSD
Completed—1
Phase 3CG5503 IR; tapentadol
Osteoarthritis+2 more
Completed
2007-08past
1
Phase 3epoetin alfa
Anemia+8 more
Completed
2008-03past
7
Phase 3Oxycodone CR
Osteoarthritis, Hip+3 more
Completed
2008-07past
1
Phase 3Rivaroxaban 2.5 mg
Acute Coronary Syndrome+3 more
Completed
2011-09past
1
Phase 2Unnamed
Correction of Refraction Error+1 more
Completed
2018-04-18past
1
Phase 3Norgestimate-ethinyl estradiol, with or without folic acid
Neural Tube Defects+2 more
Withdrawn—1
Phase 3Extended Release OROS® Paliperidone
Schizophrenia
Completed—1
Phase 3galantamine hydrobromide
Alzheimer Disease+1 more
Completed—2
Phase 3risperidone
Disruptive Behavior Disorder
Completed—1
Phase 3Becaplermin
Foot Ulcer+3 more
Terminated—1
Phase 3paliperidone palmitate
Schizophrenia
Completed—1
Phase 3galantamine
Dementia, Vascular
Completed—1
Phase 3levofloxacin
Maxillary Sinusitis
Completed—1
Phase 2topiramate
Obesity+6 more
Completed—4
Phase 3Paliperidone ER OROS®
Schizophrenia
Completed—1
Phase 3Dapoxetine
Erectile Dysfunction
Completed—1
Phase 3tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo
Sprains and Strains+1 more
Completed—1
Phase 3Tipifarnib;Zarnestra; R115777
Acute Myeloid Leukemia
Completed—1
Phase 2RWJ-445380 100 mg
Rheumatoid Arthritis
Completed
2008-01past
1
Phase 2Trabectedin
Liposarcoma,Myxoid
Completed
2010-01past
1
Phase 2Decitabine
Myelodysplastic Syndrome
Completed
2010-09past
1
Phase 2JNJ 40929837
Asthma
Completed
2011-06past
1
Phase 2JNJ-42160443
Osteoarthritis+5 more
Terminated
2011-06-30past
1
Phase 1Oral contraceptive
Healthy
Completed
2008-03past
1
Phase 1rabeprazole sodium
Gastroesophageal Reflux
Completed
2008-09past
1
Phase 1JNJ-39823277
Healthy
Completed
2009-06past
1
Phase 1JNJ-31001074
Attention Deficit Hyperactivity Disorder+1 more
Completed
2009-12past
1
Phase 1Canagliflozin
Healthy+1 more
Completed
2011-04past
1
Phase 1Canagliflozin/Probenecid
Healthy
Completed
2011-10past
1
Phase 1Tablet paracetamol, guaifenesin and phenylephrine HCL
Bioequivalence+1 more
Completed
2017-07-17past
1
Phase 1paliperidone ER
Schizophrenia+1 more
Completed—2
Phase 1Norgestimate; Ethinyl Estradiol; Folic acid.
Pharmacokinetics+2 more
Completed—1
Phase 1tapentadol (CG5503) ER 25-mg TRF
Healthy Volunteer
Completed—1
Phase 131001074/paroxetine
Healthy
Completed—1
Phase 1Topiramate oral liquid formulation;Topiramate Sprinkle formulation
Epilepsy
Completed—1
Phase 1ER OROS paliperidone
Schizophrenia
Completed—2
Phase 1Norgestimate; Ethinyl Estradiol; Folic acid
Drug Interactions+2 more
Completed—1
Phase 1tapentadol (CG5503) ER 100-mg TRF
Healthy Volunteer
Completed—1
N/AUnnamed
Common Infant Feeding Problems
Completed
1996-06past
1
N/ANicotine
Tobacco Dependence
Completed
2007-10past
1
N/AUnnamed
Myopia
Completed
2008-04past
1
N/AUnnamed
Mineral Absorption in the Urine
Completed
2008-09past
1
N/AUnnamed
Epilepsy
Completed
2009-03past
1
N/AUnnamed
Non Therapeutic Body Modification
Completed
2009-11-30past
1
N/AUnnamed
Allergy and Asthma
Completed
2009-12past
1
N/AUnnamed
Myopia
Completed
2010-03-01past
1
N/ANo intervention
Musculoskeletal Diseases
Completed
2010-04past
1
N/AUnnamed
Myopia
Completed
2010-09past
1
N/AUnnamed
Dental Devices, Home Care
Completed
2010-10-29past
1
N/AUnnamed
Blister
Completed
2010-11past
1
N/AUnnamed
Periodontal Disease+5 more
Completed
2011-12past
1
N/AUnnamed
Body Weight
Completed
2011-12past
1
N/AUnnamed
Healthy
Completed
2011-12past
1
N/AUnnamed
Atrial Fibrillation
Completed
2013-11-23past
1
N/AUnnamed
Astigmatism
Completed
2014-06past
1
N/AUnnamed
Visual Performance
Completed
2015-09past
1
N/AUnnamed
Visual Acuity
Completed
2015-09-01past
1
N/AUnnamed
Visual Acuity
Completed
2017-05-04past
1
N/AUnnamed
Healthy Volunteers
Completed
2018-02-12past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2018-03past
1
N/AUnnamed
Visual Acuity
Completed
2018-07-12past
1
N/AUnnamed
Infant Nutrition
Completed
2019-02past
1
N/AUnnamed
Visual Acuity
Completed
2019-03-25past
1
N/AUnnamed
Cataract
Completed
2019-06-05past
1
N/AUnnamed
Newborns
Terminated
2020-06-04past
1
N/AUnnamed
Visual Acuity
Completed
2020-12-09past
1
N/AUnnamed
Cataract+1 more
Completed
2021-07-14past
1
N/AUnnamed
Distal Radius Fracture
Unknown
2022-04-01past
1
N/AUnnamed
Visual Acuity
Completed
2022-12-08past
1
N/AUnnamed
Visual Acuity
Completed
2022-12-13past
1
N/AUnnamed
Vision Satisfaction in Bright Light
Completed
2023-03-10past
1
N/AUnnamed
Cataract
Terminated
2023-04-07past
1
N/AUnnamed
Fussy Infant (Baby)
Completed
2023-07-14past
1
N/AUnnamed
Thyroid Nodule
Completed
2023-09-28past
1
N/AUnnamed
Cataracts
Completed
2023-12-04past
1
N/AUnnamed
Cataracts
Completed
2023-12-21past
1
N/AUnnamed
Vision, Ocular
Completed
2024-06-12past
1
N/AUnnamed
Congenital Diaphragmatic Hernia
Active, not recruiting
2024-12-20past
1
N/AUnnamed
Cataracts
Completed
2025-04-23past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for JNJ. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.